These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31628117)

  • 1. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Chen Y; Zelnick LR; Huber MP; Wang K; Bansal N; Hoofnagle AN; Paranji RK; Heckbert SR; Weiss NS; Go AS; Hsu CY; Feldman HI; Waikar SS; Mehta RC; Srivastava A; Seliger SL; Lash JP; Porter AC; Raj DS; Kestenbaum BR;
    Am J Kidney Dis; 2021 Aug; 78(2):226-235.e1. PubMed ID: 33421453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
    Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney Clearance of Secretory Solutes Is Associated with Progression of CKD: The CRIC Study.
    Chen Y; Zelnick LR; Wang K; Hoofnagle AN; Becker JO; Hsu CY; Feldman HI; Mehta RC; Lash JP; Waikar SS; Shafi T; Seliger SL; Shlipak MG; Rahman M; Kestenbaum BR;
    J Am Soc Nephrol; 2020 Apr; 31(4):817-827. PubMed ID: 32205410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease.
    Wang K; Zelnick LR; Hoofnagle AN; Chen Y; de Boer IH; Himmelfarb J; Kestenbaum B
    Nephrol Dial Transplant; 2020 Nov; 35(11):1916-1923. PubMed ID: 31347660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study.
    Malmberg MH; Mose FH; Pedersen EB; Bech JN
    BMC Nephrol; 2020 Aug; 21(1):379. PubMed ID: 32867720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble klotho and autosomal dominant polycystic kidney disease.
    Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal tubular dysfunction in patients with cystic disease of the kidneys.
    Pabico RC; McKenna BA; Freeman RB
    Urology; 1998 May; 51(5A Suppl):156-60. PubMed ID: 9610573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Geurts F; Xue L; Kramers BJ; Zietse R; Gansevoort RT; Fenton RA; Meijer E; Salih M; Hoorn EJ;
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1426-1434. PubMed ID: 37574650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease.
    Kim H; Koh J; Park SK; Oh KH; Kim YH; Kim Y; Ahn C; Oh YK
    Nephrology (Carlton); 2019 Apr; 24(4):422-429. PubMed ID: 29797773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
    Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.